Prescription Drug Recall: Lurasidone Hydrochloride Tablets for Microbial Contamination
Sun Pharmaceutical is recalling 11,400 bottles of Lurasidone Hydrochloride 60mg tablets due to microbial contamination in manufacturing equipment. Patients taking this medication should contact their doctor or pharmacist.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with microbial contamination in manufacturing equipment and no reported illnesses or injuries, meeting the rubric threshold for Moderate severity.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling 11,400 bottles of Lurasidone Hydrochloride 60mg tablets (lot DNE0620A, expiration 05/31/2025) due to Current Good Manufacturing Practice (CGMP) deviations. Microbial contamination was identified in stagnant water within the duct of manufacturing equipment.
The affected product (NDC 47335-639-83) was distributed nationwide across the United States. Consumers currently taking this medication should contact their pharmacist or healthcare provider before discontinuing or changing their treatment.
This recall was issued by the Food and Drug Administration and classified as a Class II recall.
The recalled product
- Product
- LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE)
- Brand
- LURASIDONE HYDROCHLORIDE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Antipsychotic
- Hazard
- microbial-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #: DNE0620A Exp. 05/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LURASIDONE HYDROCHLORIDE
- HighFDA Recalls Lurasidone Hydrochloride Tablets Due to Manufacturing Equipment Contamination
FDA (Drugs) · 2024-01-31
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27